Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545037 · ClinicalTrials.gov registry record · Phase 2
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
A Phase 2 study of Irritable Bowel Syndrome, sponsored by Bio-K Plus International.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01545037: Completed Phase 2 study of Irritable Bowel Syndrome, sponsored by Bio-K Plus International.
NCT01545037 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Bio-K Plus International. The registered enrollment target is 117 participants, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01545037, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Bio-K Plus International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
Primary Outcome
The IBS-AR is a single-question dichotomous (yes/no) tool that asks subjects if they have experienced adequate relief of IBS symptoms over the past week.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
Study Locations (3)
California
- Digestive and Liver Disease Specialists A Medical Group. Inc - Garden Grove
- Sprim ALS - San Francisco
- Westlake Medical Research - Westlake Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01545037 record still lists
NCT01545037 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 142-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01545037 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01545037 about?
NCT01545037 is a clinical study titled "Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome". The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
What is the current status of trial NCT01545037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2012-07. Estimated completion is 2015-01.
What conditions does trial NCT01545037 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT01545037?
The interventions under investigation include: Placebo (OTHER), L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01545037?
This trial is sponsored by Bio-K Plus International, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01545037 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01545037's enrollment target sits among peer trials
117 19th of 47 higher than 29 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
RECRUITING · Phase 2
-
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · Phase 2
-
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
COMPLETED · Phase 2
-
Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia